Prof. Johanna A. Joyce DEPARTMENT OF ONCOLOGY http://www.joycelab.org LUDWIG INSTITUTE FOR CANCER RESEARCHUNIVERSITY OF LAUSANNE EMAIL: Johanna.Joyce@unil.chCH. DES BOVERESSES 155, TEL: +41 21 6925937 EPALINGES 1066, SWITZERLAND.

Education1990-1994 B.A. (Honors) in Genetics, Trinity College Dublin, Ireland

1995-1999 Ph.D. in Biology, University of Cambridge, England

Academic Positions and Appointments2016 Department of Oncology, University of Lausanne, Switzerland2016 Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland2014 Full Member, Sloan-Kettering Institute, New York, USA2014 Full Professor, Weill Cornell Graduate School of Medical Sciences, NY, USA2010- 2014 Associate Member, Sloan-Kettering Institute, New York, USA2010- 2014 Associate Professor, Weill Cornell Graduate School of Medical Sciences, NY, USA2005- 2010 Assistant Professor, Weill Cornell Graduate School of Medical Sciences, NY, USA 2004- 2010 Assistant Member, Sloan-Kettering Institute, New York, USA1999- 2004 Postdoctoral Fellow, University of California at San Francisco, California, USA

Laboratory of Prof. Douglas Hanahan, Department of Biochemistry1995-1999 Ph.D. Student, University of Cambridge, England

Laboratory of Dr. Paul Schofield, Department of Anatomy1994-1995 Postgraduate Researcher, Laboratory of Prof. Eamonn Maher, Department of Clinical

Genetics, University of Cambridge, England

Honours and Awards2017 EMBO Member2017 Swiss Bridge Award2017 Pandolfi Women in Cancer Research Award2012- 2015 American Cancer Society Scholar2011 Louise and Allston Boyer Young Investigator Award2007- 2011 Geoffrey Beene Junior Faculty Chair2005- 2008 Rita Allen Foundation Scholar2005- 2007 Sidney Kimmel Foundation Scholar2005- 2007 V Foundation Scholar2001- 2004 Leukemia and Lymphoma Foundation Fellow1998- 1999 Cambridge Philosophical Society Fellow1995- 1998 British Biological Sciences Research Council Fellowship

Membership of Boards and Scientific Societies2017- present Member of Editorial Board of Genes and Development2017- present Member of Editorial Board of The Journal of Experimental Medicine2015- present Member of Editorial Board of Trends in Cancer2011- present Member of Editorial Board of Cell Reports2016- present Member of External Advisory Board, IRB Barcelona2016- 2017 Elected Chairperson of AACR Tumor Microenvironment Working Group (~7200 members)2014- 2018 Steering Committee, AACR Tumor Microenvironment Working Group 2014 Scientific Advisory Board for Immuno-oncology, Daichi-Sankyo Inc.2007- 2011 Elected to Council of the International Proteolysis Society (Council Member for USA)2006- 2015 New York Academy of Sciences2000- present International Proteolysis Society 1999- present American Association of Cancer Research

Bibliography1. Olson OC, Quail DF and Joyce JA (2017). Modulation of tumour progression by an obese

microenvironment. Science, in press. 2. Quail DF, Olson OC, Bhardwaj P, Walsh LA, Akkari L, Quick M, Chen IC, Wendel N, Ben-Chetrit N,

Walker J, Holt PR, Dannenberg AJ and Joyce JA (2017). Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis via IL5 and GM-CSF. Nature Cell Biology 19: 974-987.

• Highlighted by: Nature Reviews Cancer 17: 510-511; Nature Cell Biology 19: 887-888.3. Leftin A, Ben-Chetrit N, Klemm F, Joyce JA and Koutcher JA (2017). Iron imaging reveals tumour and

metastasis associated macrophage hemosiderin deposits in breast cancer. PLoS ONE 12:e0184765. 4. Jena PV, Roxbury D, Galassi TV, Akkari L, Horoszko CP, Budhathoki-Uprety J, Pipalia NH, Haka AS,

Mittal J, Maxfield FR, Joyce JA and Heller DA (2017). A carbon nanotube optical reporter maps endolysosomal lipid accumulation and heterogeneity. ACS Nano doi: 10.1021/acsnano.7b04743. [Epub ahead of print].

5. Bakst R, Xiong H, Chen C-H, Deborde S, Lyubchik A, Zhou Y, He S, McNamara W, Lee S-L, Olson OC, Leiner IM, Marcadis A, Keith J, Al-Ahmadie H, Katabi N, Gil Z, Vakiani A, Joyce JA, Pamer E and Wong RJ (2017). Inflammatory monocytes promoted perineural invasion through CCL2 mediated recruitment and cathepsin B expression. Cancer Research doi: 10.1158/0008-5472.CAN-17-1612. [Epub ahead of print].

6. Yan D, Kowal J, Akkari L, Schuhmacher AJ, Huse JT, West BL and Joyce JA (2017). Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene doi: 10.1038/onc.2017.261. [Epub ahead of print].

7. Olson OC, Kim H, Quail D, Foley EA and Joyce JA (2017). Tumor-associated macrophages suppress the cytotoxic activity of antimitotic agents. Cell Reports 19: 101-113.

8. Quail D and Joyce JA (2017). The microenvironmental landscape of brain tumors. Cancer Cell 31: 326-341.

9. Quail D and Joyce JA (2017). Multifaceted effects of the microenvironment on tumour progression. Nature Reviews Cancer. https://www.nature.com/nrc/posters/microenvironment/micro_poster.pdf

10. Quail D and Joyce JA (2017). Molecular pathways: Deciphering mechanisms of resistance to macrophage-targeted therapies. Clinical Cancer Research 23: 876-884.

Page �2

11. Carmona-Fontaine C, Deforet M, Akkari L, Thompson CB, Joyce JA and Xavier JB (2017). Metabolic origins of spatial organization in the tumor microenvironment. PNAS 114: 2934-2939.

12. Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC and Joyce JA (2016). The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352: aad3018.

• Highlighted by: Cancer Discovery doi: 10.1158/2159-8290.CD-RW2016-100; Trends in Cell Biology 26: 562- 563; Journal of the American Medical Association 2016; 316(1):23.

13. Bowman RL, Klemm F, Akkari L, Pyonteck SM, Sevenich L, Quail DF, Dhara S, Simpson K, Gardner EE, Iacobuzio-Donahue C, Brennan CW, Tabar V, Gutin PH and Joyce JA (2016). Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Reports 17: 2445-2459.

• Highlighted by: Cancer Cell 30: 832-833.

14. Yan D, Wang H-W, Bowman RL and Joyce JA (2016). STAT3 and STAT6 signaling pathways synergize to promote cathepsin secretion from macrophages via IRE1a activation. Cell Reports 16: 2914-2927.

15. Prudova A, Gocheva V, auf dem Keller U, Eckhard U, Olson OC, Akkari L, Butler G, Fortelny N, Lange PF, McLeod J, Joyce JA# and Overall CM# (2016). TAILS N-terminomics and proteomics shows protein degradation dominates over proteolytic processing by cathepsins in pancreatic tumors. (# Joint senior authors). Cell Reports 16: 1762-1773 (Cover article).

16. Akkari L, Gocheva V, Quick M, Kester JC, Spencer AK, Garfall AL, Bowman RL and Joyce JA (2016). Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. Genes and Development 30: 220-232.

17. Edgington-Mitchell LE, Gocheva V, van der Linden W, Verdoes M, Aurelio L, Graham B, Withana NP, Lieu TM, Parker BS, Joyce JA, Storz P, Bunnett NW and Bogyo M (2016). Macrophage-derived legumain is a biomarker for murine and human pancreatitis. American Journal of Physiology 311: G458-560.

18. Akkari L and Joyce JA (2016). Microenvironmental InterFereNce of metabolism regulates chemosensitivity in cancer. Cell Research 26: 867-868.

19. Curry RC, Faivre G, Akkari L, Joyce JA, Lin O, Rosenblum M, Diamond EL and Omuro A (2016). High dose methotrexate based chemotherapy as treatment for histolytic sarcoma of the central nervous system. Leukemia and Lymphoma 57: 1961-1964.

20. Olson OC and Joyce JA (2015). Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nature Reviews Cancer 15: 712-729 (Cover article).

21. Joyce JA and Fearon DF (2015). T cell exclusion, immune privilege and the tumor microenvironment. Science 348: 74-80.

22. Klemm F and Joyce JA (2015). Microenvironmental regulation of therapeutic resistance in cancer. Trends in Cell Biology 25: 198-213.

23. Sobotič B, Vizovišek M, Vidmar R, Van Damme P, Gocheva V, Joyce JA, Gevaert K, Turk V, Turk B and Fonović M (2015). Cysteine cathepsins modulate tumorigenesis through the shedding of cell adhesion proteins and receptors. Molecular Cellular Proteomics 14: 2213-2228.

24. Hughes R, Qian BZ, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Gonzalez-Angulo AM, Joyce JA, De Palma M, Pollard JW and Lewis CE (2015). Perivascular M2 macrophage stimulate tumor relapse after chemotherapy. Cancer Research 75: 3479-3491.

Page �3

25. Brindle NR, Joyce JA, Rostker F, Lawlor ER, Swigart-Brown L, Evan G, Hanahan D, Shchors K. (2015). Deficiency for the cysteine protease cathepsin L impairs Myc-induced tumorigenesis in a mouse model of pancreatic neuroendocrine cancer. PLoS ONE 10:e0120348.

26. Zhu W, Tao L, Quick ML, Joyce JA, Qu JM and Luo ZQ (2015). Sensing cytosolic RpsL by macrophages induces lysosomal cell death and termination of bacterial infection. PLoS Pathogens 11(3):e1004704.

27. Sevenich L and Joyce JA (2014). Pericellular proteolysis in cancer. Genes and Development 28: 2331-2347.

28. Sevenich L, Bowman R, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E Brastianos P, Hahn WC, Holsinger L, Massague J, Leslie CS and Joyce JA (2014). Analysis of tumour and stroma-supplied proteolytic networks reveals a brain metastasis-promoting role for cathepsin S. Nature Cell Biology 16: 876-888.

• Highlighted by: Nature Reviews Cancer 14: 577; Cancer Discovery 4: OF11; Science Translational Medicine 6: 251ec148

29. Akkari L, Gocheva V, Kester JC, Hunter KE, Quick ML, Sevenich L, Wang HW, Peters C, Tang LH, Klimstra D, Reinheckel T and Joyce JA (2014). Distinct functions of macrophage- and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix. Genes and Development 28: 2134-2150 (Cover article).

• Highlighted by: Nature Reviews Cancer 14: 704

30. Bowman RL and Joyce JA (2014). Tumor-associated macrophages and microglia as therapeutic targets in glioblastoma. Immunotherapy 6: 663-666.

31. Alonso-Curbelo D, Riveiro-Falkenbach E, Pérez-Guijarro E, Cifdaloz M, Osterloh L, Olmeda D, Megías D, Cañon E, Karras P, Calvo TG, Gómez-López G, Graña O, Checinska A, Wang HW, Pisano DG, Pastor J, Ortiz-Romero P, Torro D, Hoek K, Rodríguez-Peralto JL, Joyce JA and Soengas MS (2014). RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway. Cancer Cell 26: 61-76.

32. Hunter KE, Palermo C, Kester JC, Simpson K, Li JP, Tang LH, Klimstra DS, Vlodavsky I and Joyce JA (2014). Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors. Oncogene 33: 1799-1808.

33. Dai P, Wang W, Cao H, Avogadri F, Dai L, Drexler I, Joyce JA, Merghoub T, Shuman S and Deng L (2014). Modified vaccinia virus Ankara triggers type I IFN production in conventional dendritic cells via a STING-mediated cytosolic DNA-sensing pathway. PLoS Pathogens 10(4):e1003989.

34. Quail DF and Joyce JA (2013). Microenvironmental regulation of tumor progression and metastasis. Nature Medicine 19: 1423-1437.

35. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail D, Olson OC, Quick M, Huse J, Teijeiro V, Setty M, Leslie C, Oei Y, Pedraza A, Zhang J, Brennan CW, Sutton JC, Holland EC, Daniel D and Joyce JA (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature Medicine 19: 1264-1272.

• Highlighted by: Nature Medicine 19: 1207-08; Nature 502: 274; Science 342: 290; Nature Reviews Cancer 13: 753; Cancer Discovery 3: 1217

36. Carmona-Fontaine C, Bucci V, Akkari L, Deforet M, Joyce JA and Xavier JB (2013). Emergence of spatial structure in the tumor microenvironment due to the Warburg effect. PNAS 110: 19402-19407.

37. Krajcovic M, Krishna S, Akkari L, Joyce JA and Overholtzer M (2013). mTor regulates phagosome and entotic vacuole fission. Molecular Biology of the Cell 24: 3736-3745.

Page �4

38. Hunter KE, Quick ML, Sadanandam A, Hanahan D and Joyce JA (2013). Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE 8: e64472.

39. Quail DF and Joyce JA (2013). Inflammation and cancer. The Molecular Biology of Cancer. Elsevier Publishing. Editors: Mendelsohn J, Gray JW, Howley PM, Israel MA, Thompson CB. Edition 4, Chapter 19, p285-295.

40. Lujambio A, Akkari L, Simon J, Grace D, Zhao Z, Bolden JE, Joyce JA, Krizhanovsky V and Lowe SW (2013). Non cell-autonomous tumor suppression by p53 in liver cancer. Cell 153: 449-460.

41. Olson OC and Joyce JA (2013). A splicing twist on metastasis. Science Translational Medicine 5:169fs2.

42. Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, Joyce JA and Fagin JA (2013). Genetic and pharmacological targeting of CSF-1/ CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS ONE 8: e54302. doi:10.1371/journal.pone.0054302.

43. Olson OC and Joyce JA (2013). Microenvironment-mediated resistance to anticancer therapies. Cell Research 23: 179-181.

44. Jacobson LS, Lima H, Goldberg MF, Gocheva V, Tsiperson V, Sutterwala FS, Joyce JA, Gapp BV, Blomen VA, Chandran K, Brummelkamp TR, Diaz-Griffero F and Brojatsch J (2013). Cathepsin-mediated necrosis controls the adaptive immune response by Th2-associated adjuvants. Journal of Biological Chemistry 288: 7841-7891.

45. Pyonteck SM, Gadea BB, Wang HW, Gocheva V, Hunter KE, Tang LH and Joyce JA (2012). Deficiency of the macrophage growth factor Csf-1 disrupts pancreatic neuroendocrine tumor development. Oncogene 31: 1459-1467.

46. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E and Joyce JA (2011). Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes and Development 25: 2465-2479 (Cover article).

• Highlighted by: Nature 480: 154; Nature Reviews Cancer 12: 2-3

47. Mason SD and Joyce JA (2011). Proteolytic networks in cancer. Trends in Cell Biology 21: 228-237 (Cover article).

48. Mason SD and Joyce JA (2011). Proteolytic cascades in invasion and metastasis. Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge Univ. Press. Editors: Lyden DC, Welsh DR, Psaila B.

49. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall A, Berman T and Joyce JA (2010). IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes and Development 24: 241-255.

• Highlighted by: Nature Reviews Cancer 10: 162-163 (2010)

50. Wang HW and Joyce JA (2010). Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle 9: 4824-4835.

51. Gocheva V, Chen X, Peters C, Reinheckel T and Joyce JA (2010). Deletion of cathepsin H reduces angiogenic switching, tumor vascularization and growth in a mouse model of pancreatic cancer. Biological Chemistry 391: 937-945.

52. Elie B, Gocheva V, Shree T, Dalrymple SA, Holsinger LJ and Joyce JA (2010). Identification and preclinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor effects in a pancreatic cancer model. Biochimie 92: 1618-1624.

53. Joyce JA and Pollard JW (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer 9: 239-252.

Page �5

54. Amankulor N, Hambardzumyan D, Pyonteck SM, Becher OJ, Joyce JA and Holland EC (2009). Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. Journal of Neuroscience 29: 10299-308.

55. Chang SH, Kanasaki K, Gocheva V, Blum G, Harper J, Moses MA, Shih SC, Manseau EJ, Nagy JA, Joyce JA, Bogyo, M, Kalluri R and Dvorak HF (2009). Roles of cathepsins B/S/L and cysteine protease inhibitors in VEGF-A-induced angiogenesis. Cancer Research 69: 4537-4544.

56. Palermo C and Joyce JA (2008). Cysteine cathepsin proteases as pharmacological targets in cancer. Trends in Pharmacological Sciences 29: 22-28.

57. Abboud-Jarrous G, Atzmon R, Peretz T, Palermo C, Gadea B, Joyce JA and Vlodavsky I (2008). Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. Journal of Biological Chemistry 283: 18167-18176.

58. Gounaris E, Tung CH, Restaino C, Maehr R, Kohler R, Joyce JA, Ploegh H, Barrett T, Weissleder R

and Khazaie K (2008). Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One 3: e2916.

59. Reinheckel T, Gocheva V, Peters C and Joyce JA (2008). Roles of cysteine proteases in tumor progression: analysis of cysteine cathepsin knockout mice in cancer models. The Cancer Degradome- Proteases and Cancer Biology. Springer Publishing.Eds. Edwards DR, Hoer-Hansen G, Blasi F, Sloane BF. p. 279-302.

60. Bell-McGuinn K, Garfall A, Bogyo M, Hanahan D, and Joyce JA (2007). Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Research 67: 7378-7385.

61. Gocheva V and Joyce JA (2007). Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6: 60- 64.

62. Sadaghiani AM, Verhelst SHL, Gocheva V, Hill K, Majerova E, Stinson S, Joyce JA and Bogyo, M (2007). Design, synthesis and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain family cysteine proteases. Chemistry and Biology 14: 499-511.

63. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, and Joyce JA (2006). Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes and Development 20: 543- 556 (Cover article).

64. Gadea BB and Joyce JA (2006). Tumor-host interactions: implications for developing anticancer therapies. Expert Reviews in Molecular Medicine 8: 1-32.

65. Joyce JA (2005). Therapeutic targeting of the tumor microenvironment. Cancer Cell 7: 513-520.66. Joyce JA, Freeman C, Meyer-Morse N, Parish C, and Hanahan D (2005). A functional heparan sulfate

mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24: 4037-4051.

67. Joyce JA, Hanahan D (2004). Multiple roles for cysteine cathepsins in cancer. Cell Cycle 3: 57-60.

68. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai, F-Y, Greenbaum D, Hager JH, Bogyo M and Hanahan D (2004). Cathepsin cysteine proteases are effectors of angiogenesis and invasive growth during multistage tumorigenesis. Cancer Cell 5: 443-453 (Cover article).

• Highlighted by: Nature Reviews Cancer 4: 501; Cancer Cell 5: 409-410

Page �6

69. Joyce JA*, Laakkonen P*, Bernasconi M, Bergers G, Ruoslahti E and Hanahan D (2003). Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4: 393-403.

• Highlighted by: Nature Reviews Cancer 4: 9 (2004); Cancer Cell 4: 331-333 (2003)

70. Schofield PN, Joyce JA, Lam WK, Grandjean V, Ferguson-Smith A, Reik W and Maher ER (2001). Genomic imprinting and cancer; new paradigms in the genetics of neoplasia. Toxicology Letters 120: 151-160.

71. Catchpoole DJ, Smallwood AV, Joyce JA, Murrell A, Lam WK, Tang TW, Munroe D, Reik W, Schofield PN, Maher ER (2000). Mutation analysis of H19 and NAP1L4 (hNAP2) candidate genes and IGF2 DMR2 in Beckwith-Wiedemann syndrome. Journal of Medical Genetics 37: 212-215.

72. Smilinich NJ, Day CD, Fitzpatrick GV, Caldwell GM, Lossie AC, Cooper PR, Smallwood AC, Joyce JA, Schofield PN, Reik W, Nicholls RD, Weksberg R, Driscoll DJ, Maher ER, Shows TB, Higgins MJ (1999). A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. PNAS 96: 8064-8069.

73. Lam WW, Hatada I, Ohishi S, Mukai T, Joyce JA, Cole TR, Donnai D, Reik W, Schofield PN, Maher ER (1999). Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. Journal of Medical Genetics 36: 518-523.

74. Joyce JA, Ferguson-Smith AC (1999). Genomic imprinting: its role in development and disease. Development: Genetics, Epigenetics and Environmental Regulation. (Eds. Russo VEA, Cove DJ, Edgar LG, Jaenisch R, Salamini F.) p. 421-434.

75. Joyce JA, Schofield PN (1998). Genomic imprinting and cancer. Molecular Pathology 51: 185-190.76. Catchpoole D, Lam WW, Valler D, Temple IK, Joyce JA, Reik W, Schofield PN, Maher ER (1997).

Epigenetic modification and uniparental inheritance of H19 in Beckwith-Wiedemann syndrome. Journal of Medical Genetics 34: 353-359.

77. Joyce JA, Lam WK, Catchpoole DJ, Jenks P, Reik W, Maher ER, Schofield PN (1997). Imprinting of IGF2 and H19: lack of reciprocity in sporadic Beckwith-Wiedemann syndrome. Human Molecular Genetics 6: 1543-1548.

78. Brassett C, Joyce JA, Froggatt NJ, Williams G, Furniss D, Walsh S, Miller R, Evans DG, Maher ER (1996). Microsatellite instability in early onset and familial colorectal cancer. Journal of Medical Genetics 33: 981-985.

79. Froggatt NJ*, Joyce JA*, Evans DG, Lunt PW, Koch DJ, Ponder BJ, Maher ER (1996). MSH2 sequence variations and inherited colorectal cancer susceptibility. European Journal of Cancer 32A: 178.

80. Froggatt NJ, Joyce JA, Davies R, Gareth D, Evans R, Ponder BA, Barton DE, Maher ER (1995). A frequent MSH2 mutation in hereditary non-polyposis colon cancer syndrome. Lancet 345: 727.

81. Joyce JA, Froggatt NJ, Davies R, Evans DG, Trembath R, Barton DE, Maher ER (1995). Molecular genetic analysis of exons 1 to 6 of the APC gene in non-polyposis familial colorectal cancer. Clinical Genetics 48: 299-303.

MANUSCRIPTS IN PREPARATION, REVIEW AND REVISION

82. Zomer A and Joyce JA. Microenvironmental regulation of cancer metastasis and therapeutic efficacy. Invited review for The Journal of Experimental Medicine, in preparation.

Page �7

83. Leftin A, Ben-Chetrit N, Joyce JA and Koutcher JA. Label-free imaging and therapeutic targeting of iron deposits in breast tumor macrophages. (Manuscript in review).

84. Chang WK, Bowman, RL, Joyce JA and Xavier JB. Ecological modeling of cell-cell interactions in cancer growth and treatment. (Manuscript in review).

85. Yang JL, Bowman RL, Pelossof R, Joyce JA and Leslie CS. Modeling tumor-stroma interactions that mediate innate resistance to targeted cancer therapies. (Manuscript in review).

Research Funding SupportCURRENT GRANTS

Swiss Cancer LeaguePI: Johanna Joyce 374,300 CHF 1/10/2017- 30/9/2020‘Targeting Tumor-Associated Macrophages to Enhance Therapeutic Efficacy in Gliomas’The goals of this research grant include determining how treatment with radiation, chemotherapy or tyrosine kinase inhibitors affects macrophage numbers and phenotypes. We aim to elucidate the mechanisms by TAMs interfere with therapeutic efficacy in gliomas, and investigate whether targeting TAMs can enhance response to a panel of different therapeutic agents.

Breast Cancer Research Foundation Investigator Grant PI: Johanna Joyce $750,000/ 730,000 CHF 1/10/2016- 30/9/2019‘Targeting the Roles of Tumor-Associated Macrophages in Breast Cancer Chemoresistance’Our objectives include investigating the mechanisms by which tumor-associated macrophages confer resistance to chemotherapy, using animal models of breast cancer, cell-based assays and patient samples.

National Cancer Institute NIH R01 CA181355PI: Johanna Joyce$2,617,025 total (641,225 CHF in direct costs transferred to UNIL)1/7/2014- 31/5/2019 (1/7/2016- 31/5/2019 in Switzerland)‘Investigating and Targeting Tumor-Associated Macrophages (TAMs) in the Glioma Microenvironment’The goals of this R01 grant are to elucidate the mechanisms by which TAMs regulate glioma cell malignancy, and determine how CSF-1R inhibitors interfere with this reciprocal communication to delay and block glioma progression. We will determine how TAMs are initially educated by glioma cells, and then re-educated by CSF-1R inhibition in the glioma microenvironment. We will investigate which glioma cell signaling pathways are enhanced by TAMs, and establish the downstream effectors that are critical to CSF-1R inhibition efficacy in vivo. Finally, we will determine whether gliomas develop resistance to CSF-1R inhibition, and identify the underlying mechanisms.

Roche Strategic AlliancePI: Johanna Joyce 1,496,100 CHF 1/11/2016- 30/10/2019Co-PI: Michele DePalma, EPFL‘Combinatorial Strategies for Therapeutically Targeting the Glioma Microenvironment’The aims of this research grant are to develop and evaluate a series of combinatorial approaches to therapeutically target different cellular components of the tumor microenvironment in gliomas. These include targeting macrophages/ microglia, the vasculature, and the adaptive immune system.

Cancer Research UK Grand ChallengePI: Greg Hannon £20,000,000 1/5/2017- 30/4/2023Co-PIs: Johanna Joyce, Sam Aparicio, Carlos Caldas, Simon Tavaré, Bernd Bodenmiller, Nicholas Walton, Owen Harris, Shankar Balasubramanian, Xiaowei Zhuang, Ed Boyden

Page �8

‘IMAXT: Imaging and Molecular Annotation of Xenografts and Tumors’The goal of this multidisciplinary Grand Challenge grant is to combine established techniques with new technology that our team will invent to build 3D tumours containing every single cell and cell type in the breast cancer microenvironment, which can then be analysed using virtual reality. This new approach to understanding breast cancer could change how the disease is diagnosed, treated and managed.

Swiss Bridge AwardPI: Johanna Joyce 250,000 CHF 1/1/2018- 30/12/2019‘Investigating and Therapeutically Targeting Neutrophils in Brain Metastasis’The goals of this project are to explore the potential roles of neutrophils in brain metastasis, based on our preliminary data showing these cells are a major component of the brain tumor microenvironment in patients with brain metastases. We will include analyses of patient samples, mouse models and cell-based assays in our investigation, with the goal of determining if neutrophils modulate brain metastasis.

COMPLETED GRANTS

Breast Cancer Research Foundation Investigator Grant PI: Johanna Joyce $2,250,000 10/1/2009- 9/30/2016‘Understanding how Bone Marrow-Derived Cells Contribute to the Development of Metastatic Breast Cancer and Enhance Resistance to Chemotherapy’

Alan and Sandra Gerry Foundation, Center for Metastasis Research, MSKCCPI: Johanna Joyce $400,000 8/1/2014- 7/31/2016‘Investigation of the Microenvironmental Transcriptome in Breast to Brain Metastasis’

ONO Pharmaceuticals Investigator Grant PI: Johanna Joyce $255,000 7/1/2015- 6/30/2016‘Small Molecule Inhibitor Screen for M2 Macrophage Reprogramming’

Tri-Institutional Stem Cell Initiative (Tri-SCI)/ Starr FoundationPI: Scott Blanchard $994,633 7/1/2013-9/30/2016 Co-PIs: Johanna Joyce, Theresa Vincent‘Targeting the Cancer Stem Cell Ribosome for Therapeutic Purpose’

American Cancer Society Research Scholar Grant PI: Johanna Joyce $720,000 1/1/2012- 12/31/2015‘Interleukins, Cathepsin Proteases and Macrophages in the Tumor Microenvironment’

MSKCC-Weizmann Collaborative Initiative/ Rosenkranz FoundationPI: Johanna Joyce $180,000 3/1/2014- 12/31/2015 Co-PI: Irit Sagi ‘Investigating Tumor-Stromal Interactions in Pancreatic Neuroendocrine Tumors’

Cycle for Survival FoundationPI: Johanna Joyce $300,000 9/1/2012- 8/31/2015‘Investigating and Targeting the Tumor-Promoting Functions of Cathepsin Proteases in Gliomas’

Health Research Science Board of New YorkPI: Johanna Joyce $360,000 1/9/2013-8/31/2015

Page �9

‘Investigating and Targeting Interactions Between Cancer and the Microenvironment in Breast to Brain Metastasis’

National Cancer Institute NIH U54 CA148967PI: Chris Sander $14,910,476 2/1/2010-1/31/2015 Co-PIs: Gregoire Altan-Bonnet, Jackie Bromberg, Johanna Joyce, Christina Leslie, Joao Xavier ‘Systems Biology of Diversity in Cancer’

Cycle for Survival FoundationPI: Johanna Joyce $385,000 9/1/2011- 8/31/2014‘Developing a Unique Mouse Model of Poorly Differentiated Pancreatic Neuroendocrine Tumors as a Preclinical Trial Platform’

Cycle for Survival FoundationPI: Johanna Joyce $460,000 9/1/2011- 8/31/2014‘Evaluating CSF-1R Inhibition as a Novel Target in Gliomagenesis’

Alan and Sandra Gerry Foundation, Metastasis Research CenterPI: Johanna Joyce $400,000 8/1/2012-7/31/2014‘Developing Novel Strategies to Target Tumor Cell-Macrophage Interactions in Brain Metastasis’

National Cancer Institute NIH R01 CA125162PI: Johanna Joyce $2,166,000 7/1/2007-5/31/2012‘Dissecting the Function of Cysteine Cathepsins in the Tumor Microenvironment’

National Cancer Institute NIH U54 CA126518PI: Eric Holland $6,442,577 10/1/2006-9/30/2011Co-PIs: Johanna Joyce, Joan Massague‘Tumor-Host Interactions in the Tissue Microenvironment of Brain Tumors and Metastases’

Geoffrey Beene Foundation $389,892 3/1/2007- 12/30/2011Endowed Junior Faculty Chair to Dr. Joyce, provided salary support.

Emerald Foundation PI: Johanna Joyce $150,000 1/1/2007-12/31/2010‘Understanding and Targeting the Roles of Cathepsin Proteases in Cancer Growth and Metastasis’

Rita Allen Foundation, Scholar AwardPI: Johanna Joyce $150,000 9/1/2005-8/31/2008‘Molecular Dissection of the Tumor Microenvironment’

The V Foundation for Cancer Research, Scholar Award PI: Johanna Joyce $100,000 9/1/2005-8/31/2007‘Dissecting the Role of Cysteine Cathepsins in Cancer’

Sidney Kimmel Foundation for Cancer Research, Scholar Award PI: Johanna Joyce $200,000 7/1/2005-6/30/2007‘Genetic Analysis of Cathepsins in Cancer Development’

Page �10

Invited Presentations2017 Distinguished Clinicians Conference, Dept. Of Oncology, CHUV, Lausanne, Switzerland.

Cell Symposium on “Neuro-Immune Axis”, Sitges, Spain.Inaugural Crick International Cancer Conference, The Francis Crick Institute, London, UK. EACR conference “Immune Defense is the Best Attack: Immune-Oncology Breakthroughs”, Barcelona, Spain.Women’s Cancer Conference, Barcelona, Spain.Centre for Integrative Genomics Seminar Series, UNIL, Lausanne, Switzerland.Lola and John Grace Distinguished Lecture, ISREC/ EPFL, Lausanne, Switzerland.

2016 AACR Annual Meeting, Major Symposium on “Inflammation and Cancer”, New Orleans, USA. SSORL/ SSAI Annual Meeting, Joint Plenary Session, Montreux, Switzerland.Vall d’Hebron Hospital Seminar Series, Barcelona, Spain.Novartis Seminar Series, Basel, Switzerland. SCCL/ ISREC Symposium on “Horizons of Cancer Biology and Therapy”, Lausanne, Switzerland.European Society of Molecular Oncology Annual Conference, Copenhagen, Denmark.NKI (Netherlands Cancer Institute) Seminar Series, Amsterdam, The Netherlands.Basel Breast Consortium on “Personalised Breast Cancer Treatments”, Basel, Switzerland. San Raffaele Scientific Institute Seminar Series, Milan, Italy.

2015 AACR Annual Meeting, Major Symposium on “Tumor Microenvironment”, Philadelphia. AACR Annual Meeting, TME Working Group Town Hall Meeting, Philadelphia.Immunotherapy Session, 26th Annual “Cancer Progress” Conference, New York. Princeton University, Molecular Biology Seminar Series, New Jersey. CSHL Conference on “The Biology of Cancer: Microenvironment, Metastasis and Therapeutics”AACR Special Conference on “Advances in Brain Cancer Research”, Washington DC.Massachusetts General Hospital, Center for Cancer Research Seminar Series, Charlestown, MA.Cell Symposium on “Cancer, Inflammation and Immunity”, Sitges, Spain.“Emerging Concepts in Host Response to Cancer” Symposium, MD Anderson, Texas.Brain Tumor Center Seminar Series, MD Anderson, Texas.New York University, NYU Perlmutter Cancer Center Seminar Series, New York.Yale University, Immunobiology Seminar Series, New Haven, CT.

2014 AACR Special Conference on “Cellular Heterogeneity in the Tumor Microenvironment”, San Diego.Keystone Symposium on “Inflammation, Infection and Cancer”, Whistler, Canada.University of Oxford, Department of Pathology Seminar Series, England.CRUK Cambridge Institute, University of Cambridge, England. Gordon Conference on “Molecular and Cellular Basis of Breast Development and Cancer Progression”, Il Ciocco, Italy.EMBL Monterotondo Seminar Series, Rome, Italy.Gordon Conference on “Proteolytic Enzymes and their Inhibitors: Dysfunction in Disease, Mechanism and Therapeutic Targeting ”, Il Ciocco, Italy.“Origins of Cancer” Annual Van Andel Institute Symposium, Michigan.Brain Tumor Center Retreat, MSKCC, New York.

2013 “Control of Cell Motility in Development and Cancer” Conference, Freiburg, Germany.TME-NYC Symposium on “Tumor Microenvironment: Mechanisms and Therapeutic Implications”

Page �11

AACR Annual Meeting, Meet the Expert Session, Washington DC.Danish Cancer Society Research Center Seminar Series, Copenhagen, Denmark.Herbert Irving Comprehensive Cancer Center Annual Symposium on Advances in Cancer Research: “Tumor Microenvironment”, Columbia University, New York.Keynote Lecture, Annual Graduate Student Research Symposium, Wayne State Univ., Detroit.Pharmacology Seminar Series, Wayne State University, Detroit.University of Pennsylvania, Hem-Onc Seminar Series, Philadelphia.“Gathering Around Cancer” Conference, Dublin, Ireland.International Proteolysis Society Meeting, Cape Town, South Africa.Nature Medicine Symposium, Cancer Therapeutics 2013: From Bench to Bedside, San Diego. Mount Sinai School of Medicine, Immunology Institute Seminar Series, New York. American Society of Cell Biology Annual Meeting, New Orleans.

2012 Keystone Symposium on “Inflammation during Carcinogenesis”, Dublin, Ireland. “Cell Death in Cancer” Conference, St. Malo, France.Oregon Health & Science University, Cell Biology Seminar Series, Portland, Oregon.Gerstner Sloan Kettering Graduate School Retreat, Mohonk, NY.Gordon Research Seminar (Keynote Lecture) and Gordon Conference (Invited Talk) on “Proteolytic Enzymes and their Inhibitors”, Il Ciocco, Italy. Brain Tumor Center Seminar Series, MSKCC.Koch Institute for Integrative Cancer Research, Oncology Seminar Series, MIT, Boston.

2011 AACR Annual Meeting, Major Symposium on “Microenvironmental Regulation of Invasion and Metastasis”, Orlando, Florida.Idibell Cancer Conference on “Metastasis and Angiogenesis”, Barcelona, Spain.CMTRA Conference on “Molecular Therapeutics of Cancer”, Asilomar, California.Lucille Castori Symposium on “Inflammation and Cancer of the Gastrointestinal Tract”, MSKCC.CCSB/ ICBP Symposium on “Systems Biology of Diversity in Cancer”, New York.Department of Surgery Research Conference, MSKCC.American Pancreatic Association Annual Meeting, Chicago, Illinois.Max F. Perutz Laboratories, University of Vienna, Austria.

2010 AACR Special Conference “Cancer Genomics, Epigenomics, and the Development of Novel Therapeutics”, Hawaii.Annual Meeting of the Irish Association for Cancer Research, Galway, Ireland.AACR Annual Meeting, “Mouse Models of Invasion and Metastasis” Session, Washington DC.Gordon Conference on “Proteolytic Enzymes and their Inhibitors”, Il Ciocco, Italy.Swiss Institute for Cancer Research/ ISREC, Seminar Series, Lausanne, Switzerland.Swiss Federal Institute of Technology/ ETH, Cell Biology Seminar Series, Zurich, Switzerland.VIB Vesalius Research Center, Seminar Series, University of Leuven, Belgium.“Molecular Insights in Cancer Progression and Invasion”, Biomedicum Helsinki Conference.Lucille Castori Symposium on “Tumor-Infiltrating Myeloid Cells”, MSKCC, New York.Amgen Seminar Series, South San Francisco, California.Cincinnati Children’s Hospital, Molecular and Developmental Biology Seminar Series, Ohio.Columbia University, Department of Genetics and Development Seminar Series, New York. Nature/ CNIO Cancer Symposium “Frontiers in Tumour Progression”, Madrid, Spain.Institut Curie, Cancer Genetics and Biology Unit, Paris, France.

Page �12

2009 AACR Special Conference on “Mouse Models of Cancer”, San Francisco, California.Stanford University, Cancer Biology Seminar Series, California.Albert Einstein School of Medicine, Cancer Center Seminar Series, New York.Geoffrey Beene Cancer Center Annual Retreat, Pennsylvania.International Symposium on Cancer Biology: “Cancer- Found in Translation”, Queens University Belfast, Ireland.Computational Biology Department Seminar Series, MSKCC, New York. “Innovative Approaches for Cancer Treatment” Symposium, Osaka Medical Center, Japan.Translational Medicine Seminar Series. Memorial Sloan Kettering Cancer Center, New York.2nd Annual BIDMC Cancer Center Symposium on “Newest Findings in Targeted Therapies for

Personalized Treatment of Breast Cancer”, Harvard Medical School, Boston, MA.

2008 Cambridge Research Institute Inaugural Symposium: “Unanswered Questions in the Tumour Microenvironment”, Cambridge, England. Annual Meeting of the Irish Association for Cancer Research, Newcastle, N. Ireland.5th Annual “Pacific Coast Proteases” Meeting, San Diego, California.Phase I Working Group Seminar Series. Memorial Sloan Kettering Cancer Center, New York.Geoffrey Beene Cancer Center Annual Retreat, Pennsylvania.IRB Conference on “Metastasis”, Barcelona, Spain.Department of Surgery Grand Rounds Seminar Series, MSKCC, New York.Symposium on Gastrointestinal Malignancies, Philadelphia, Pennsylvania.New York University, Department of Pathology Seminar Series, New York.STARGET Tumor Microenvironment Conference, Stockholm, Sweden.

2007 International Proteolysis Society Meeting, Patras, Greece.Trinity College Dublin, Department of Genetics Seminar Series, Ireland.AstraZeneca-MSKCC Science Day, Memorial Sloan Kettering Cancer Center, New York.SKI Scientific Colloquium, Memorial Sloan Kettering Cancer Center, New York.Massachusetts General Hospital, CMIR Seminar Series, Harvard Medical School, Boston, MA.Symposium on Metastasis, Memorial Sloan Kettering Cancer Center, New York.Translational Medicine Seminar Series, Memorial Sloan Kettering Cancer Center, New York.“Frontiers in Science” Symposium, Memorial Sloan Kettering Cancer Center, New York.“Major Trends in Modern Cancer Research” Symposium, MSKCC, New York.Proteolix Seminar Series, South San Francisco, California.

2006 Keynote Lecture at International Conference on “Cysteine Proteinases and their Inhibitors”, Portoroz, Slovenia.Annual Meeting of the International Society for Fibrinolysis and Proteolysis, San Diego, CA.Genentech Seminar Series, South San Francisco, California.Department of Surgery Grand Rounds Seminar Series, MSKCC, New York.Department of Pediatrics Grand Rounds Seminar Series, MSKCC, New York.

2005 AACR Special Conference on “Cancer, Proteases and the Tumor Microenvironment”. Florida.University of Freiburg, Institute for Molecular Medicine Seminar Series, Germany. University of Frankfurt, Department of Cardiology Seminar Series, Germany.

2004 Keystone Conference on “Mouse Models of Human Cancer”, Keystone, Colorado. Celera Seminar Series, Celera Genomics, South San Francisco, California.

Page �13

2003 International Proteolysis Society Meeting, Nagoya, Japan.American Society for Cell Biology, Annual Meeting, San Francisco, California.American Society for Biochemistry and Molecular Biology, Annual Meeting, San Diego, CA.

2002 Gordon Conference “Proteolytic Enzymes and their Inhibitors”, New Hampshire.Breast Cancer Center Seminar Series. Department of Pharmacology, Wayne State University, Detroit, Michigan.

Manuscript and Grant Reviews2005- present Regular reviewer for:

Nature, Cell, Science, Nature Medicine, Nature Cell Biology, Nature Reviews Cancer, Nature Biotechnology, Genes and Development, Cancer Cell, Immunity, Cell Stem Cell, Developmental Cell, Molecular Cell, Cell Reports, Cancer Discovery, Science Translational Medicine, Science Signaling, Chemistry and Biology, Journal of Experimental Medicine, Journal of Clinical Investigation, Oncogene, Cancer Research, J Biol Chem, PNAS

2016- present Grant Reviewer, Swiss Cancer League 2013- present Grant Reviewer, Italian Association for Cancer Research (AIRC) 2012- present Grant Reviewer, Science Foundation Ireland2014 Grant Reviewer, Fondation contre le Cancer, Belgium2013 Proposal Reviewer, Centre Européen de Recherche en Biologie et en Médecine, France2012- 2013 Grant Reviewer, Cycle for Survival Foundation2012 Grant Reviewer, Erwin Schroedinger Program, Austrian Science Fund (FWF)2012 Grant Reviewer, Geoffrey Beene and Metastasis Research Centers, MSKCC2011 Grant Reviewer, Human Frontiers Science Program, France2009- 2012 Grant Reviewer, Cancer Prevention and Research Institute of Texas (CPRIT), ‘Basic

Cancer Biology’ review panel chaired by Dr. Tyler Jacks2009 Grant Reviewer, “Integration of Mouse Models into Human Cancer Research”, NCI/ NIH

Study Section2009 Grant Reviewer, “Multi-Team Translational Awards”, Breast Cancer Research Program,

Department of Defense2009 Grant Reviewer, Yorkshire Cancer Research Society, UK2008, 2014 Grant Reviewer, Brain Tumor Center, MSKCC

Mentoring and Leadership Roles

ORGANISATION OF NATIONAL AND INTERNATIONAL MEETINGS

2017 Co-Organizer of EACR conference “Immune Defense is the Best Attack: Immune-Oncology Breakthroughs”, Barcelona, Spain.

2017 Member of Immunotherapy of Cancer Organising Committee, ESMO 2018 Annual Meeting.2016 Chair of Gordon Research Conference on “Proteolytic Enzymes and their Inhibitors”, Italy.2016 Co-Organizer of Nature-MSKCC conference on “Cancer as an Evolving and Systemic

Disease”, MSKCC, New York.2016, 2018 Co-Organizer of ISREC-SCCL conferences on “Horizons of Cancer Biology and Therapy”,

Lausanne, Switzerland.2016 Co-Organizer of Cell Symposium on “Hallmarks of Cancer”, Ghent, Belgium.2016 Member of Translational Research Organising Committee, ESMO 2017 Annual Meeting.

Page �14

2015 Co-Organizer of TME-NYC Annual Symposium, CSHL, New York.2014 Primary organizer of Keystone Conference on “Inflammation, Infection and Cancer”

Co-Organizers: Drs. Frances Balkwill, Timothy Wang2014 Program Committee for 2014 AACR Annual Meeting2014 Co-Organizer with Dr. Joan Massague of Inaugural “Center for Metastasis Research”

Symposium, MSKCC, New York. 2014 Vice Chair of Gordon Research Conference on “Proteolytic Enzymes and their Inhibitors”,

Chair: Dr. James Whisstock2013 Co-Organizer with Dr. Vivek Mittal of Inaugural TME-NYC Annual Symposium on “Tumor

Microenvironment: Mechanisms and Therapeutic Implications”2011 Co-Chairperson, Program Committee for 2011 AACR Annual Meeting

Co-Chairperson, Education Committee for 2011 AACR Annual Meeting

2010 Co-Organizer with Dr. Eric Pamer of Lucille Castori Symposium on “Tumor-Infiltrating Myeloid Cells”, MSKCC

CHAIRING MEETING SESSIONS, SCIENTIFIC OUTREACH

2016 Invited speaker for the 5th Annual Lecture, Women in Science, Montreux, Switzerland.2016 Chair, Session on ‘The Tumor Niche: Local and Systemic Effects’, Nature conference on

“Cancer as an Evolving and Systemic Disease”, MSKCC, New York.2015 Chair, Session on “Brain Tumor Microenvironment”, AACR Special Conference on

“Advances in Brain Cancer Research”, Washington DC. 2015 Co-Chair, Session on “Tumor Microenvironment and Metastasis”, CSHL Conference on

“The Biology of Cancer: Microenvironment, Metastasis and Therapeutics”2015 Co-Chair, Session on “Tumor-Associated Macrophages”, Cell Symposium on “Cancer,

Inflammation and Immunity”, Sitges, Spain.2014 Co-Chair of opening and closing sessions of joint Keystone conferences on “Inflammation,

Infection and Cancer” and “Immune Evolution in Cancer”, Whistler, Canada 2014 Chair, Session on “Tumor Microenvironment Intersection with Immunity”, Second Annual

TME-NYC Symposium on “Tumor Microenvironment: Composition, Mechanisms and Consequences for Therapy”

2014 Careers Panel, Gordon Conference on “Molecular and Cellular Basis of Breast Development and Cancer Progression”, Il Ciocco, Italy

2014 Chair, Tumor Biology I Session, MSKCC Brain Tumor Center Retreat, NY2014 ‘The Art of Science’, a collaboration between artists and scientists, Ligo Project, NY 2013 Chair, Session on “Metastasis and the Impact of the Microenvironment”, First Annual

TME-NYC Symposium on “Tumor Microenvironment: Mechanisms and Therapeutic Implications”

2013 Co-Chair of "Cell Biology of Cancer Cells and of the Tumor Microenvironment" Session, American Society of Cell Biology Annual Meeting, New Orleans

2013 Chair, “Tumor Heterogeneity” Session, Nature Medicine Cancer Therapeutics Symposium, San Diego

2012 Chair, Session on “Tumor Promotion by Inflammatory Cells”, Keystone Symposium on Inflammation during Carcinogenesis, Dublin, Ireland

2012 Speaker, Careers Panel, Gordon Research Seminar on “Proteolytic Enzymes and their Inhibitors”, Il Ciocco, Italy

Page �15

2011 Co-Chair, Session on “Cancer and Cell Survival”, International Proteolysis Society Meeting, San Diego, California

2011 Chair, Major Symposium on “Microenvironmental Regulation of Invasion and Metastasis”, AACR Annual Meeting, Orlando, Florida

2009- 2011 Geoffrey Beene Cancer Research Retreat Organizing Committee, MSKCC2009 Chair, Session on “Tumour Microenvironment”, International Symposium on Cancer

Biology, Belfast, Ireland2009 Co-Chair, Session on “Cancer and Metastasis”, International Proteolysis Society Meeting,

Queensland, Australia2008 Group Leader, Responsible Conduct of Research Course, MSKCC2007-2011 Elected to Council of International Proteolysis Society (Council Member for USA)2007 Speaker, GSK “Frontiers in Science” Symposium for College Students2007 Speaker, “Major Trends in Modern Cancer Research”, MSKCC Science Symposium for

High School Students2006 Speaker, “The Academic Job Hunt”, New York Academy of Sciences2006-2008 Organizer of Cancer Biology and Genetics Program Seminar Series, MSKCC2006, 2008 Speaker, Careers Panel, Summer Undergraduate Research Program, MSKCC2006, 11, 13 Speaker, Scientific Seminar Series, Summer Undergraduate Research Program, MSKCC2006 Co-Chair, Session on “Cysteine Proteases in Cancer”, 5th International Conference on

Cysteine Proteinases and their Inhibitors, Portoroz, Slovenia2005 Co-Chair, “Proteolytic Systems and Cancer” , AACR Annual Meeting, Anaheim, CA

JUNIOR FACULTY, POSTDOC AND STUDENT MENTORSHIP

2017 External faculty mentor for Dr. Manuel Valiente, Junior Group Leader, CNIO, Madrid 2011 Co-Leader of Postdoc/ Faculty forum on “Mentor-Mentee Relationships”, MSKCC, NY2010- 2015 Advisory Board, GSK Women in Science program (run by GSK students), MSKCC2009- 2015 Student Advisor, Tri-Institutional MD-PhD/ FACES Program, New York2008- 2015 Mentor for Junior Clinical Faculty, Department of Medicine, MSKCC 2006- 2008 Co-Director, SKI Summer Undergraduate Research Program, MSKCC2005- 2012 First Year Mentor, Gerstner Sloan-Kettering Graduate Program2005- 2010 Founded and organised monthly MSKCC Junior Faculty meetings for Assistant and Associate Members to discuss issues including successfully establishing a lab, hiring

technicians and postdocs, recruiting students, writing papers and grants etc.

Academic Service2017- present Agora Pilotage Committee, UNIL/ CHUV/ EPFL 2017- present Program Committee for PhD in Immunology and Cancer, UNIL 2016- present In Vivo Imaging Platform Committee, UNIL 2014- 2015 Executive Committee, Center for Metastasis Research, MSKCC, New York 2014- 2015 Founded and organised “Tumor Immunology and Microenvironment” work-in-progress monthly meetings for faculty and select trainees across MSKCC 2013 Planning Committee for GSK 2014 Commencement 2011- 2015 Member of Training Committee on NIH T32 Grant for Translational Research in Oncology

Training Program (CBG and HOPP)2011 Search Committee for Associate Dean, GSK Graduate Program, MSKCC

Page �16

2009-11, 2013 Faculty Search Committee, Human Oncology & Pathogenesis (HOPP) Program, MSKCC2008 Tri-Institutional MD-PhD Program Admissions Committee2008 Admission to Candidacy Exam (ACE) Committee, Weill Cornell/ SKI BCMB Program2005- 2015 Faculty Search Committee, Cancer Biology and Genetics (CBG) Program, MSKCC2005- 2015 Interviewer of students for three MSKCC graduate programs (GSK, Cornell, MD/PhD)2005- 2008 Selection Committee, SKI Summer Undergraduate Research Program (SURP)2004- 2009 Curriculum Committee, Gerstner Sloan-Kettering Graduate Program, MSKCC

Teaching Experience2017- Lecturer in MSc of Medical Biology program in Immunology and Cancer Course, UNIL2011- 2015 Lecturer in Molecular Oncology Course, New York University (NYU)2010- 2015 Lecturer in Cancer Biology Course for clinical oncology clinical fellows, MSKCC2010 Co-leader of Cancer Biology Focus Group for Weill/ Cornell BCMB Program on “Tumor

Microenvironment, Invasion and Metastasis”2008- 2011 Lecturer in Frontiers in Biomedical Sciences, Tri-Institutional MD-PhD Program, New York2005- 2010 Lecturer in Molecular Genetics Core Course for Weill/ Cornell BCMB Program2006 Co-leader of Cancer Biology Focus Group for Weill/ Cornell BCMB Program on “Invasion

and Metastasis”2005- 2015 Lecturer in Cancer Biology and Genetics Core Course for CCNY/ MSKCC Partnership, City

College, CCNY, New York2005- 2015 Lecturer in Cancer Biology Core Course for Gerstner Sloan-Kettering Graduate School

Mentorship and Supervision of Trainees

CURRENT POSTDOCTORAL FELLOWS

2014- present Dr. Florian Klemm (M.D., Ph.D., Göttingen University, Germany)DFG Fellowship, Germany (2014-2016)Fondation Medic Prize (2017-2018)

2016- present Dr. Joanna Kowal (Ph.D., Institut Curie, Paris, France)2017- present Dr. Anoek Zomer (Ph.D., Hubrecht Institute, Utrecht, Netherlands)

Human Frontier Science Program Fellowship (2017-2019)2017- present Dr. Klara Soukup (Ph.D., Medical University of Vienna, Austria)

2017- present Dr. Spencer Watson (Ph.D., Oregon Health and Science University, Portland, USA)

CURRENT GRADUATE STUDENTS

2017- present Davide Croci (M.Sc. ETH Zurich, Switzerland) UNIL Ph.D. program in Cancer and Immunology

2017- present Vladimir Wischnewski (M.Sc. University of Freiburg, Germany) UNIL Ph.D. program in Cancer and Immunology

2017- present Roeltje Maas (M.D., Radbaud University, Netherlands) UNIL Ph.D. program in Cancer and Immunology

FORMER GRADUATE AND MEDICAL STUDENTS 2005- 2010 Vasilena Gocheva, Ph.D., Cornell/ SKI BCMB Graduate Program

Frank L. Horsfall Studentship (2007-2008) Page �17

Geoffrey Beene Fellowship (2008-2010)Vincent du Vigneaud Award (2009)

Current position: Programs Manager, Koch Institute for Cancer Research, MIT, USA

2006- 2008 Alfred Garfall, M.D. (New York University)HHMI Medical Student Training Fellowship (2006-2007)

Current position: Assistant Professor, Dept. of Medicine, University of Pennsylvania, USA

2006- 2010 Tanaya Shree, Ph.D., Tri-Institutional MD-PhD ProgramCurrent position: Clinical fellow at Stanford Medical School, USA

2006- 2012 Stephanie Pyonteck, Ph.D., Cornell/ SKI BCMB Graduate ProgramNIH T31 Training Grant (2008-2010)

Current position: Postdoctoral fellow in Prof. Chris Rongo’s lab, Rutgers University, USA

2008- 2012 Karen Hunter, Ph.D., Gerstner Sloan-Kettering Graduate Program Grayer Fellowship (2009-2010)

Current position: Manager of Clinical and Scientific Operations, Celmatix, New York, USA

2008- 2013 Hao-Wei Wang, M.D., Ph.D., Cornell/ SKI BCMB Graduate ProgramTaiwan Merit Fellowship (2007-2009)

Frank L. Horsfall Studentship (2010-2011) Vincent du Vigneaud Award (2011)

Current position: Clinical fellow at National Institutes of Health, Bethesda, USA

2013- 2014 Marie Groth, M.Sc. student through University of Freiburg, GermanyCurrent position: Ph.D. student, DKFZ, Heidelberg, Germany

2011- 2016 Robert Bowman, Ph.D., Gerstner Sloan-Kettering Graduate ProgramGeoffrey Beene Fellowship (2011-2012) NIH Kirschstein F31 Training Fellowship (2012-2016)

Current position: Postdoctoral fellow in Dr. Ross Levine’s lab, MSKCC

2010- 2016 Oakley Olson, Ph.D., Gerstner Sloan-Kettering Graduate ProgramGeoffrey Beene Fellowship (2010-2011) Grayer Fellowship (2011-2012) Silvian Foundation Fellowship (2010-2012) NIH Kirschstein F31 Training Fellowship (2012-2016)

FORMER POSTDOCTORAL AND CLINICAL FELLOWS 2005-2007 Dr. Katherine Bell-McGuinn (M.D./ Ph.D., Johns Hopkins Medical School, MD)

Current position: Assistant Attending Member, Memorial Hospital, MSKCC, New York, USA Assistant Professor, Cornell Medical School, New York, USA.

2005-2008 Dr. Bedrick Gadea (Ph.D., Harvard University, MA) Recipient of American Cancer Society Fellowship

Current position: Founder and partner of The Dedham Consulting Group, New York, USA

2006-2008 Dr. Carmela Palermo (Ph.D., Robert Wood Johnson Medical School/ UMDNJ, NJ) Recipient of American Cancer Society Fellowship

Current position: Senior Medical Science Liaison, Johnson & Johnson

2006-2010 Dr. Steven Mason (Ph.D., UC San Diego, CA) Recipient of National Cancer Institute (NIH F32) Fellowship

Current position: VP, Medical and Scientific Services at Healthcare Consultancy Group

Page �18

2009-2012 Dr. Alberto Jimenez Schuhmacher (Ph.D., Univ. Autonoma of Madrid, Spain) Recipient of Ramón Areces Foundation Fellowship (2009-2011)

Ibercaja Foundation Fellowship (2011-2012)Current position: Principal Investigator, Biomedicine Center, Zaragoza, Spain

2010- 2015 Dr. Lisa Sevenich (Ph.D., University of Freiburg, Germany) Recipient of DFG Fellowship, Germany (2012-2014)

Center for Metastasis Research Fellowship, MSKCC (2014-2015)Current position: Assistant Professor, Georg Speyer Haus Institute, Frankfurt, Germany

2014- 2015 Dr. Janneke Jaspers (Ph.D., Netherlands Cancer Institute, The Netherlands)Rubicon Fellowship, Dutch Organization for Scientific Research (2015-2017)

Current position: Postdoc in Brentjens lab, MSKCC, USA 2014- 2016 Dr. Bianca Santomasso (M.D., Ph.D., Tri-Institutional MD-PhD Program, NY)

Recipient of Brain Tumor Center Fellowship, MSKCC (2014-2015)Current position: Assistant Attending Neuro-oncologist, MSKCC

2015- 2016 Dr. Nir Ben-Chetrit (Ph.D., The Weizmann Institute, Israel)Current position: Postdoc in Landau lab, Weill Cornell Medical School, USA

2012- 2016 Dr. Dongyao Yan (Ph.D., Rush University, Chicago)Current position: Scientist, NantOmics, Rockville, Maryland, USA

2011- 2017 Dr. Leila Akkari (Ph.D., Montpellier University, France) Recipient of Brain Tumor Center Fellowship, MSKCC (2012-2014) American Brain Tumor Association Fellowship (2014-2016) Current position: Assistant Professor, NKI Netherlands Cancer Institute, Amsterdam

2012- 2017 Dr. Daniela Quail (Ph.D., University of Western Ontario, Canada) Recipient of Canadian Institutes of Health Research Fellowship (2013-2016) Current position: Assistant Professor, McGill University, Montreal, Canada

UNDERGRADUATES AND HIGH SCHOOL STUDENTS 6- 8/ 2005 Erica Jackson (University of Notre Dame), SURP Program, Shaps Scholar Awardee6- 8/ 2006 Tara Berman (University of Pennsylvania), SURP Program

Current position: Medical resident, St. Luke’s-Roosevelt Hospital Center, NY.6/07- 8/09 Karoline Dubin (Spence High School, NY), Part-time during school year 2007-2009

Full-time, summer 2008 and 2009.6- 8/ 2008 Alison Spencer (University of Rochester), SURP Program, Shaps Scholar Awardee

Current position: Graduate student, Gerstner Sloan Kettering Graduate School, MSKCC1/09- 6/10 Jemila Kester (City College, NY), Part-time during school year 2009-2010

SURP Program, summer 2009.Current position: Graduate student, Harvard Medical School, MA

6- 8/ 2011 Audrey Robbins (Virginia Tech), SURP Program9-12/ 2011 Anja Faulhaber (University of Freiburg, Germany), M.Sc. internship program1-8/ 2012 Darenne Poyser (City College, NY), Part-time during school year 20121-6/ 2012 Jason Lela (City College, NY), Part-time during school year 20125/12- 2/13 Mina Aziz (Hunter College, NY), Part-time during school year 2012-20136- 8/ 2013 Marlie Fisher (University of Colorado at Boulder), SURP Program6- 8/ 2014 Colette Fox (Milwaulkee School of Engineering), NCI ICBP Summer Program

Page �19

CURRENT AND FORMER RESEARCH TECHNICIANS 2016- present Lucie Tillard (Baccalauréat Sciences et Technologies de Laboratoire (STL), France) 2015- 2016 Nisarg Shah (M.A. New York University, NY)

Current position: Lab manager for Rudin lab, MSKCC, NY2005- 2006 Danxia Ke (M.Sc. Stony Brook University, NY)

Current position: Lab manager, MD Anderson Cancer Center, TX2010- 2011 Jemila Kester (B.Sc. City College, City University of New York, NY)

Current position: Graduate Student, Harvard Medical School, MA2008-10, 2013 Benelita Tina Elie (B.Sc. Brooklyn College, City University of New York, NY)

Current position: Graduate Student, Brooklyn College, City University of New York, NY2006- 2014 Kenishana Simpson (B.Sc. Ithaca College, NY)

Current position: Oncology nurse specialist, MSKCC, NY2012- 2015 Marsha Quick (B. Sc. University of Washington, WA)

Current position: Research Scientist, Seattle Genetics, WA2007- 2015 Xiaoping Chen (B.Sc. Southeastern University, China)

Current position: Senior Research Technician, Anti-tumor Assessment Facility, MSKCC

Graduate Student CommitteesTHESIS ADVISORY COMMITTEES 2017- present Luigi Mazzeo (Dotto lab), UNIL Immunology and Cancer Graduate Program2017- present Marie Zuffery (Ciriello lab), UNIL Immunology and Cancer Graduate Program 2017- present Fabien Franco (Ho lab), UNIL Immunology and Cancer Graduate Program 2016- present Marine Bruand (Coukos lab), UNIL Immunology and Cancer Graduate Program 2013- 2016 Julie Yang (Leslie lab), Tri-Institutional Computational Biology Graduate Program2013- 2015 I-Li Tan (Joyner lab), Weill Cornell BCMB Graduate Program2013- 2014 Kelsey Temprine (White lab), Gerstner Sloan-Kettering Graduate Program, New York.2011- 2015 William Chang (Xavier lab), Tri-Institutional Computational Biology Graduate Program.2011- 2015 Jenny Karo (Sun lab), Gerstner Sloan-Kettering Graduate Program, New York.2010- 2014 Ruth Franklin (Ming Li lab), Weill Cornell Immunology Graduate Program, New York.2010- 2014 Yu-Ching Peng (Joyner lab), Weill Cornell BCMB Graduate Program, New York.2010- 2014 Hyejin Choi (Mittal lab), Weill Cornell BCMB Graduate Program, New York.2010- 2013 Evelyn Yao (Ventura lab), Weill Cornell BCMB Graduate Program, New York.2008- 2012 Nicholas Gauthier (Sander lab), Gerstner Sloan-Kettering Graduate Program, New York.2008- 2013 Katherine Hall (Blobel lab), Weill Cornell BCMB Graduate Program, New York.2008- 2014 Kelly Gillen (Giancotti lab), Weill Cornell BCMB Graduate Program, New York.2007- 2011 Amanda Katz (Holland lab), Weill Cornell BCMB Graduate Program, New York.2006- 2010 April Chan (Lyden lab), Weill Cornell BCMB Graduate Program, New York.2006- 2011 Selena Granitto (Lyden lab), Weill Cornell BCMB Graduate Program, New York.2006- 2011 Guocan Wang (Pandolfi lab), Weill Cornell BCMB Graduate Program, New York.2005- 2008 David Padua (Massague lab), Tri-Institutional MD-PhD Program, New York.2005- 2009 Paula Bos (Massague lab), Weill Cornell BCMB Graduate Program, New York.2005- 2013 Svetlana Pavlovic (Benezra lab), Weill Cornell BCMB Graduate Program, New York.2005- 2006 Gaorov Gupta (Massague lab), Tri-Institutional MD-PhD Program, New York.

Page �20

THESIS DEFENSE EXAMINATIONS

2016 Caroline Baer (DePalma lab) EPFL Graduate Program, Lausanne, Switzerland.2016 Ada Sala-Hojman (Seaone lab), University of Barcelona Graduate Program, Spain

(External Examiner)2016 Giulia Escobar (Naldini lab), San Raffaele Scientific Institute/ University of Milan Graduate

Program, Italy (External Examiner) 2016 Julie Yang (Leslie lab), Tri-Institutional Computational Biology Graduate Program2015 Jenny Karo (Sun lab), Gerstner Sloan-Kettering Graduate Program, New York.2014 Yu-Ching Peng (Joyner lab), Weill Cornell BCMB Graduate Program, New York.2014 Kelly Gillen (Giancotti lab), Weill Cornell BCMB Graduate Program, New York.2014 Ruth Franklin (Ming Li lab), Weill Cornell Immunology Graduate Program, New York.2014 Hyejin Choi (Mittal lab), Weill Cornell BCMB Graduate Program, New York.2014 Nilgun Tasdemir (Lowe lab), Watson School of Biological Sciences, Cold Spring Harbor

Laboratories, NY (External Examiner)2013 Evelyn Yao (Ventura lab), Weill Cornell BCMB Graduate Program, New York.2013 Bo Rafn (Jaattela and Kallunki labs), Danish Cancer Society Research Center,

Copenhagen, Denmark (External Examiner)2013 Katherine Hall (Blobel lab), Weill Cornell BCMB Graduate Program, New York.2013 Svetlana Pavlovic (Benezra lab), Weill Cornell BCMB Graduate Program, New York.2013 Ken Pitter (Holland lab), Tri-Institutional MD-PhD Program, New York (Chairperson)2012 Nicholas Gauthier (Sander lab), Gerstner Sloan-Kettering Graduate Program, New York.2011 Guocan Wang (Pandolfi lab), Weill Cornell BCMB Graduate Program, New York. 2011 Selena Granitto (Lyden lab), Weill Cornell BCMB Graduate Program, New York.2011 Amanda Katz (Holland lab), Weill Cornell BCMB Graduate Program, New York.2010 April Chan (Lyden lab), Weill Cornell BCMB Graduate Program, New York.2010 Alice Hawley Berger (Pandolfi lab), Weill Cornell BCMB Graduate Program (Chairperson)2009 Paula Bos (Massague lab), Weill Cornell BCMB Graduate Program, New York.2009 Binzi Qian (Pollard lab), Albert Einstein College of Medicine, NY (External Examiner)2008 David Padua (Massague lab), Tri-Institutional MD-PhD Program (Chairperson)2007 Mario Chamorro (Varmus lab), Weill Cornell BCMB Program (Chairperson)2006 Kathryn O’Reilly (Rosen lab), Tri-Institutional MD-PhD Program, New York.2006 Gaorov Gupta (Massague lab), Tri-Institutional MD-PhD Program (Chairperson)

THESIS PROPOSAL EXAMINATIONS

2012 Kari Fischer (Mittal lab), Weill Cornell BCMB Graduate Program (Chairperson) 2009 Semanti Mukherjee (Klein lab), Gerstner SKI Graduate Program (Chairperson)

Shannon Yu (Baylies lab), Gerstner SKI Graduate Program (Chairperson) 2008 Eric Alonzo (San’t Angelo lab), Gerstner SKI Graduate Program (Chairperson)

Manuel Viotti (Hadjantonakis lab), Weill Cornell BCMB ProgramYuji Shi (Jiang lab), Weill Cornell BCMB Program (Chairperson)Edo Israely (Blobel lab), Weill Cornell BCMB Program

Page �21